Generex Biotechnology Corporation
33 Harbour Square
535 articles with Generex Biotechnology Corporation
Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans
Generex is pleased to announce that in the coming week, the company will finalize a financing commitment to advance the strategic goals of the company.
Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, at 4:00 p.m. Eastern
Management to Provide Update on Acquisitions, Financing, Expansion Initiatives & Strategic Plans
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen® Wound Conforming Gel Matrix with Three Dosage Options
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Olaregen Therapeutix Inc., a subsidiary of Generex Biotechnology will launch three doses of FDA 510K-Cleared Excellagen, the company’s wound conforming gel matrix that is designated as a Cellular & Tissue Based Product or CTP for wound healing.
Medisource Partners is an FDA registered distributor with an extensive portfolio of medical and surgical products including bone grafts and biologics
Generex Biotechnology Announces Investor Conference Call; Management to Provide Update on Acquisitions, Financing Initiatives & Strategic Plans
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Wednesday, January 16th, at 4:00 p.m. to update investors on the previously announced and pending acquisitions that offer significant value to the Generex parent company
Pantheon Medical manufactures a line of FDA cleared products used in orthopedic surgeries including screws, plates, implants, and anchors
Closes transaction to complete 51% acquisition of Olaregen Therapeutix Plans Commercial Launch of FDA-cleared Excellagen®
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision for Generex as an integrated life science holdings company.
Announces closing of 51% acquisition of regenerative medicine company Regentys™
J.P. Morgan annual healthcare conference & biotech showcase to be held January 7 – 9 at the Westin St. Francis Hotel, San Francisco, CA
-- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to provide an update on operational and strategic developments at NuGenerex Immuno-Oncology (previously Antigen Express), a wholly-owned subsidiary.
Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix
Collagen Solutions & Berkshire Sterile Manufacturing to Supply Excellagen® for Q1 Launch
Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force and Distribution Team for the Commercial Launch of Excellagen
150+ Wound care consultants the core of national launch of Excellagen for the treatment of surgical wounds, diabetic foot ulcers, venous skin ulcers, and other hard to treat wounds
Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis
Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.”
Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting of Innovations in Wound Healing
Presents MATRIX Clinical Trial Data and Holds Clinical Advisory Board Meeting on the use of Excellagen for the Treatment of Diabetic Ulcers and Surgical Wounds
Generex Biotechnology Receives IND Approval from FDA for Phase II Combination Study using AE37 plus Keytruda® (pembrolizumab) for the Treatment of Triple Negative Breast Cancer
The combination study builds on previous clinical studies of both AE37 and Keytruda®. AE37, a cancer vaccine, was the subject of a 300 patient prospective, randomized and single-blinded Phase II study in patients with breast cancer.
Generex Biotechnology Corporation completed payment of its 20 to 1 common stock dividend on November 30, 2018.
Slide Deck and transcript available for download
Secures remaining 49% of HDS for $1.00
Puration, Inc. (USOTC: PURA) today announced being featured in a Goldman Small Cap Research update on Generex Biotechnology Corp. (USOTC: GNBT)